Overview

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17

Status:
Terminated

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the efficacy and safety of donepezil hydrochloride (Aricept) in the treatment of the cognitive dysfunction shown by children with Down syndrome, aged 11 to 17.

Phase:

Phase 3

Details

Lead Sponsor:

Eisai Inc.

Collaborator:

Pfizer

Treatments:

Donepezil